Jagsonpal Pharmaceuticals Shares Jump 5% Following Buyback Plan and 200% Dividend Declaration

Synopsis: Jagsonpal Pharmaceuticals Limited is in focus after announcing a 200% dividend (Rs.4 per share) and a Rs.40 crore share buyback at Rs.250 per share, alongside its Q4 FY26 results. The company reported revenue of Rs.67.4 crore and net profit of Rs.8.8 crore, reflecting steady operational performance and strong shareholder returns. 

Jagsonpal Pharmaceuticals, a niche player in the domestic pharmaceutical space, has delivered a combination of stable financial performance and strong capital return initiatives. The company’s board has recommended a Rs. 4 per share dividend (200% payout) and approved a buyback of up to 16 lakh shares, signaling confidence in its financial position. 

As of April 2026, Jagsonpal Pharmaceuticals shares are trading at Rs. 206, with a market capitalization of Rs. 1,383 crore and today the shares went up to  4.92% as compared to their previous close of Rs. 203. The stock has recorded a 52-week high of Rs. 302 and a low of Rs. 155, indicating notable volatility over the past year. The company trades at a P/E ratio of 31.0, reflecting moderate valuation for a mid-cap pharma player. Its ROCE stands at 22.7% and ROE at 17.3%, indicating strong capital efficiency and profitability. 

During Q3 FY26 (December 2025 quarter), the company reported revenue of Rs.75.9 crore, while net profit stood at Rs.11 crore. Operating profit came in at Rs.16.3 crore, with an operating margin of 22.30%, indicating strong profitability during the quarter. Profit before tax was Rs.14.5 crore, reflecting efficient cost control and healthy operational performance.  

In Q4 FY26 (March 2026 quarter), Jagsonpal reported revenue of Rs.67.4 crore, compared to Rs.75.9 crore in Q3, reflecting a sequential decline of ~11%. Net profit stood at Rs.8.8 crore, down from Rs.11 crore in Q3, indicating a ~20% decline QoQ, though still showing 33.1% YoY growth. Operating profit came in at Rs.11.2 crore, with operating margins at 17.38%, compared to 22.30% in Q3, highlighting margin compression. Profit before tax also declined to Rs.11.8 crore from Rs.14.5 crore in the previous quarter. 

The company has recommended a final dividend of Rs.4 per share (200%), subject to shareholder approval. Additionally, it has approved a buyback of up to 16 lakh shares at Rs.250 per share, aggregating to Rs.40 crore, with May 4, 2026 set as the record date. 

Jagsonpal Pharmaceuticals presents a balanced investment case, combining steady financial performance with strong shareholder return initiatives. While Q4 showed a temporary dip in sequential performance, the company continues to deliver solid year-on-year growth. 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Jagsonpal Pharmaceuticals Shares Jump 5% Following Buyback Plan and 200% Dividend Declaration appeared first on Trade Brains.